comprehensive -WSS

comprehensive

author：comprehensive 2025-09-03 09:26:16 - browse：6744

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： After Optum profits sink, UnitedHealth makes changes

leisure time

entertainment

WSS

Megan Rapinoe shares emotional post following US Women's World Cup exit

TytoCare raises $49 million to build out AI

Aspartame and sugar

What to know about the judge who will handle the Trump case

Treatments for cramps don't cut it. Why aren't there better options?

Biogen’s boardroom scandal saddles CEO with first crisis

knowledge

comprehensive

hotspot

Virginia high school admissions case could be legal follow

ProMED, early warning system on disease outbreaks, in peril

Anesthesiologist group: stop taking Ozempic before surgery

Hospitals are dialing back on venture capital investing

Medical records are filled with copy

The drug industry sees a key ally in the Senate prevail

Wildfire smoke exposes gaps in outdoor worker protections

My superpower is killing ticks

Drug repurposing or repositioning? The language matters

A cyberattack has disrupted hospitals and health care in several states

focus

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

BMS, looking to build heart drug business, turns to AI for diagnosis

Treatments for cramps don't cut it. Why aren't there better options?

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

TytoCare raises $49 million to build out AI

hotspot

leisure time

entertainment

leisure time